SG11202106765XA - Anti-pd-1 binding proteins and methods of use thereof - Google Patents

Anti-pd-1 binding proteins and methods of use thereof

Info

Publication number
SG11202106765XA
SG11202106765XA SG11202106765XA SG11202106765XA SG11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA
Authority
SG
Singapore
Prior art keywords
methods
binding proteins
proteins
binding
Prior art date
Application number
SG11202106765XA
Other languages
English (en)
Inventor
David Johnson
Adam Adler
Rena Mizrahi
Yoong Lim
Michael Asensio
Original Assignee
Gigagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen Inc filed Critical Gigagen Inc
Publication of SG11202106765XA publication Critical patent/SG11202106765XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202106765XA 2018-12-27 2019-12-27 Anti-pd-1 binding proteins and methods of use thereof SG11202106765XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785660P 2018-12-27 2018-12-27
PCT/US2019/068824 WO2020140088A1 (en) 2018-12-27 2019-12-27 Anti-pd-1 binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202106765XA true SG11202106765XA (en) 2021-07-29

Family

ID=71127358

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106765XA SG11202106765XA (en) 2018-12-27 2019-12-27 Anti-pd-1 binding proteins and methods of use thereof

Country Status (12)

Country Link
US (1) US20220064302A1 (pt)
EP (1) EP3902822A4 (pt)
JP (1) JP2022516073A (pt)
KR (1) KR20210121046A (pt)
CN (1) CN113544146A (pt)
AU (1) AU2019414968A1 (pt)
BR (1) BR112021012667A2 (pt)
CA (1) CA3124971A1 (pt)
IL (1) IL284157A (pt)
MX (1) MX2021007692A (pt)
SG (1) SG11202106765XA (pt)
WO (1) WO2020140088A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210121047A (ko) * 2018-12-27 2021-10-07 기가젠, 인코포레이티드 항-pd-l1 결합 단백질 및 이의 사용 방법
WO2022115343A1 (en) * 2020-11-30 2022-06-02 Merck Sharp & Dohme Corp. Arginase 1 binders for inhibiting arginase 1 activity
CA3216770A1 (en) * 2021-04-26 2022-11-03 Tomoki Yoshihara Anti-clec12a antibodies and uses thereof
CN117769569A (zh) * 2021-06-11 2024-03-26 纪念斯隆-凯特琳癌症中心 抗uPAR抗体和其用途
WO2023034566A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-dll3 antibodies and uses thereof
WO2024044732A2 (en) * 2022-08-25 2024-02-29 Bright Biopharmaceutical Multispecific antibodies and uses thereof
WO2024050371A1 (en) * 2022-08-29 2024-03-07 Fred Hutchinson Cancer Center Antibodies with novel fc modification combinations that increase antibody function

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2406760C3 (ru) * 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
CN109069628A (zh) * 2016-01-14 2018-12-21 Bps生物科学有限公司 抗pd-1抗体及其用途
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用

Also Published As

Publication number Publication date
JP2022516073A (ja) 2022-02-24
MX2021007692A (es) 2021-09-30
WO2020140088A1 (en) 2020-07-02
CA3124971A1 (en) 2020-07-02
EP3902822A1 (en) 2021-11-03
KR20210121046A (ko) 2021-10-07
US20220064302A1 (en) 2022-03-03
EP3902822A4 (en) 2022-12-28
BR112021012667A2 (pt) 2022-01-11
CN113544146A (zh) 2021-10-22
IL284157A (en) 2021-08-31
AU2019414968A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
IL281783A (en) SIRPa type binding proteins and methods of using them
IL281683A (en) DLL3 binding proteins and methods of use
IL275782A (en) Multispecific antigen binding proteins and methods of use thereof
IL276731A (en) Antibodies against CD73 and methods of using them
EP3635013A4 (en) NECTIN-4 BINDING PROTEINS AND PROCESSES FOR USE
IL261666A (en) Related proteins and methods of using them
IL261432A (en) Induced binding proteins and methods of use
IL288071A (en) Epcam binding proteins and methods of use
IL284157A (en) Anti-pd-1 binding proteins and methods of using them
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
IL278821A (en) Anti-SIRPA antibodies and methods of using them
IL269074A (en) Proteins that bind anti-TIGIT antigens and methods of using them
IL279201A (en) Multispecific binding proteins and methods of using them
IL284156A (en) Binding proteins against ctla-4 and methods of using them
IL270214A (en) Anti-sortilin antibodies and methods of using them
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
IL279227A (en) Anti-SIGLEC-7 antibodies and methods of using them
IL284364A (en) Anti-pd-l1 binding proteins and methods of using them
IL283231A (en) dpep-1 binding factors and methods of use